Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CFTR | P13569 | 1/20 | 0.56 |
| ▸ | SIRT1 | Q96EB6 | 17/20 | 0.56 |
| ▸ | FTO | Q9C0B1 | 1/20 | 0.51 |
| ▸ | SIRT2 | Q8IXJ6 | 2/20 | 0.47 |
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | CASP6 | P55212 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13650098 | 0.97 | CFTR (0.53) | CFTRSIRT1FTOSIRT2SIRT3 | |
| SCHEMBL13650082 | 0.91 | SIRT1 (0.50) | CFTRSIRT1FTOSIRT2SIRT3 | |
| SCHEMBL13650086 | 0.89 | MEN1 (0.45) | CFTRSIRT1MEN1KMT2APOLB | |
| SCHEMBL12594724 | 0.88 | CFTR (0.61) | CFTRSIRT1FTOSIRT2SIRT3 | |
| SCHEMBL12594765 | 0.88 | CFTR (0.56) | CFTRSIRT1FTOSIRT2SIRT3 | |
| SCHEMBL13650093 | 0.87 | SIRT1 (0.55) | CFTRSIRT1FTOMEN1KMT2A | |
| SCHEMBL12594706 | 0.87 | CFTR (0.55) | CFTRSIRT1FTOSIRT2SIRT3 | |
| SCHEMBL12648741 | 0.87 | CFTR (0.55) | CFTRSIRT1FTOSIRT2SIRT3 | |
| SCHEMBL13650099 | 0.87 | MEN1 (0.44) | CFTRSIRT1FTOMEN1KMT2A | |
| SCHEMBL12872566 | 0.86 | CFTR (0.52) | CFTRSIRT1FTOSIRT2SIRT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090253799-A1 | DIVALENT HYDRAZIDE COMPOUND CONJUGATES FOR INHIBITING CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2009-10-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090253799-A1 | DIVALENT HYDRAZIDE COMPOUND CONJUGATES FOR INHIBITING CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | CFTR, SLC26A4, SLC26A3 | CFTR 1/4885SIRT1 3338/4885FTO 4877/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.